Compounding Pharmacy Market Size to Record US$ 28.19 Billion by 2032

According to a recent research report titled “Compounding Pharmacy Market (By Therapeutic Area: Pain Management, Hormone Replacement, Dermal Disorders, Nutritional Supplements, Others; By Route of Administration: Oral, Topical, Parenteral, Others; By Application: Pediatric, Geriatric, Adult, Veterinary; By Compounding Type: Pharmaceutical Dosage Alteration, Pharmaceutical Ingredient Alteration, Others; By Sterility; By Distribution Channels) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032″ published by Precedence Research, the global compounding pharmacy market size is projected to touch around USD 28.19 billion by 2032 and growing at a CAGR of 6.57% over the forecast period 2023 to 2032. This comprehensive study examines various factors and their impact on the growth of the compounding pharmacy market.

Key Takeaways:

• North America is expected to dominate the market during the forecast period.
• By therapeutic area, the pain management segment is expected to dominate the market over the forecast period.
• By route of administration, the oral segment is expected to hold the largest revenue share over the forecast period.
• By distribution channel, the hospital pharmacy segment is expected to dominate the market over the forecast period.

The report primarily focuses on the volume and value of the compounding pharmacy market at the global, regional, and company levels. At the global level, the report analyzes historical data and future prospects to present an overview of the overall market size. Regionally, the study emphasizes key regions such as North America, Europe, the Middle East & Africa, Latin America, and others.

Furthermore, the research report provides specific segmentations based on regions (countries), companies, and all market segments. This analysis offers insights into the growth and revenue trends during the historical period of 2017 to 2032, as well as the projected period. By understanding these segments, it becomes possible to identify the significance of different factors that contribute to market growth.

Download a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/3185

The research also highlights significant progressions in both organic and inorganic growth strategies within the global compounding pharmacy market. Numerous companies are placing emphasis on new product launches, gaining product approvals, and implementing various business expansion tactics. Moreover, the report presents detailed profiles of firms operating in the compounding pharmacy market, along with their respective market strategies. Additionally, the study concentrates on prominent industry participants, furnishing details such as company profiles, product offerings, financial updates, and noteworthy advancements.

Compounding Pharmacy Market Report Scope

Also read: Grow Lights Market Size to Record US$ 24.44 Billion by 2032

Major Key Points Covered in Report:

Executive Summary: It includes key trends of the electric vehicle fuel cell market related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the electric vehicle fuel cell market based on production and revenue.

Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.

Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the Electric vehicle fuel cell market.

Market Segments: This part of the report discusses product, application and other segments of the electric vehicle fuel cell market based on market share, CAGR, market size, and various other factors.

Research Methodology: This section discusses the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.

Market Key Players

The report incorporates company profiles of key players in the market. These profiles encompass vital information such as product portfolio, key strategies, and a comprehensive SWOT analysis for each player. Additionally, the report presents a matrix illustrating the presence of each prominent player, enabling readers to gain actionable insights. This facilitates a thoughtful assessment of the market status and aids in predicting the level of competition in the compounding pharmacy market.

Some of the prominent players in the compounding pharmacy market include

• Fresenius Kabi
• Fagron NV
• B. Braun Medical Inc.
• Rx3 Compounding Pharmacy
• Clinigen Group PLC
• Dougherty’s Pharmacy, Inc.
• Lorraine’s Pharmacy
• Wedgewood Pharmacy
• Institutional Pharmacy Solutions
• Mcguff compounding pharmacy services

Compounding Pharmacy Market Segmentations 

By Therapeutic Area

• Pain Management
• Hormone Replacement
• Dermal Disorders
• Nutritional Supplements
• Others

By Route of Administration

• Oral
• Topical
• Parenteral
• Others

By Application

• Pediatric
• Geriatric
• Adult
• Veterinary

By Compounding Type

• Pharmaceutical Dosage Alteration (PDA)
• Pharmaceutical Ingredient Alteration (PIA)
• Currently Unavailable Pharmaceutical Manufacturing (CUPM)
• Others

By Sterility

• Sterile
• Non-sterile

By Distribution Channel

• Compounding Pharmacy
• Hospital Pharmacy
• Others

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Why should you invest in this report?

This report presents a compelling investment opportunity for those interested in the global compounding pharmacy market. It serves as an extensive and informative guide, offering clear insights into this niche market. By delving into the report, you will gain a comprehensive understanding of the various major application areas for compounding pharmacy. Furthermore, it provides crucial information about the key regions worldwide that are expected to experience substantial growth within the forecast period of 2023-2030. Armed with this knowledge, you can strategically plan your market entry approaches.

Moreover, this report offers a deep analysis of the competitive landscape, equipping you with valuable insights into the level of competition prevalent in this highly competitive market. If you are already an established player, it will enable you to assess the strategies employed by your competitors, allowing you to stay ahead as market leaders. For newcomers entering this market, the extensive data provided in this report is invaluable, providing a solid foundation for informed decision-making.

Some of the key questions answered in this report:       

• What is the size of the overall Compounding pharmacy market and its segments?
• What are the key segments and sub-segments in the market?
• What are the key drivers, restraints, opportunities and challenges of the Compounding pharmacy market and how they are expected to impact the market?
• What are the attractive investment opportunities within the Compounding pharmacy market?
• What is the Compounding pharmacy market size at the regional and country-level?
• Who are the key market players and their key competitors?
• What are the strategies for growth adopted by the key players in Compounding pharmacy market?
• What are the recent trends in Compounding pharmacy market? (M&A, partnerships, new product developments, expansions)?
• What are the challenges to the Compounding pharmacy market growth?
• What are the key market trends impacting the growth of Compounding pharmacy market?

Table of Content:

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Compounding Pharmacy Market 

5.1. COVID-19 Landscape: Compounding Pharmacy Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Compounding Pharmacy Market, By Therapeutic Area

8.1. Compounding Pharmacy Market, by Therapeutic Area, 2023-2032

8.1.1. Pain Management

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Hormone Replacement

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Dermal Disorders

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. Nutritional Supplements

8.1.4.1. Market Revenue and Forecast (2020-2032)

8.1.5. Others

8.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Compounding Pharmacy Market, By Route of Administration

9.1. Compounding Pharmacy Market, by Route of Administration, 2023-2032

9.1.1. Oral

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Topical

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Parenteral

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Compounding Pharmacy Market, By Application

10.1. Compounding Pharmacy Market, by Application, 2023-2032

10.1.1. Pediatric

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Geriatric

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Adult

10.1.3.1. Market Revenue and Forecast (2020-2032)

10.1.4. Veterinary

10.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Compounding Pharmacy Market, By Compounding Type

11.1. Compounding Pharmacy Market, by Compounding Type, 2023-2032

11.1.1. Pharmaceutical Dosage Alteration (PDA)

11.1.1.1. Market Revenue and Forecast (2020-2032)

11.1.2. Pharmaceutical Ingredient Alteration (PIA)

11.1.2.1. Market Revenue and Forecast (2020-2032)

11.1.3. Currently Unavailable Pharmaceutical Manufacturing (CUPM)

11.1.3.1. Market Revenue and Forecast (2020-2032)

11.1.4. Others

11.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 12. Global Compounding Pharmacy Market, By Sterility

12.1. Compounding Pharmacy Market, by Sterility, 2023-2032

12.1.1. Sterile

12.1.1.1. Market Revenue and Forecast (2020-2032)

12.1.2. Non-sterile

12.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 13. Global Compounding Pharmacy Market, By Distribution Channel

13.1. Compounding Pharmacy Market, by Distribution Channel, 2023-2032

13.1.1. Compounding Pharmacy

13.1.1.1. Market Revenue and Forecast (2020-2032)

13.1.2. Hospital Pharmacy

13.1.2.1. Market Revenue and Forecast (2020-2032)

13.1.3. Others

13.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 14. Global Compounding Pharmacy Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.1.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.1.3. Market Revenue and Forecast, by Application (2020-2032)

14.1.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.1.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.1.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.1.7. U.S.

14.1.7.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.1.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.1.7.3. Market Revenue and Forecast, by Application (2020-2032)

14.1.7.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.1.8. Market Revenue and Forecast, by Sterility (2020-2032)

14.1.8.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.1.9.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.1.9.3. Market Revenue and Forecast, by Application (2020-2032)

14.1.9.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.1.10. Market Revenue and Forecast, by Sterility (2020-2032)

14.1.11. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.1.11.1.

14.2. Europe

14.2.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.2.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.2.3. Market Revenue and Forecast, by Application (2020-2032)

14.2.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.2.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.2.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.2.7.

14.2.8. UK

14.2.8.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.2.8.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.2.8.3. Market Revenue and Forecast, by Application (2020-2032)

14.2.9. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.2.10. Market Revenue and Forecast, by Sterility (2020-2032)

14.2.10.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.2.11. Germany

14.2.11.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.2.11.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.2.11.3. Market Revenue and Forecast, by Application (2020-2032)

14.2.12. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.2.13. Market Revenue and Forecast, by Sterility (2020-2032)

14.2.14. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.2.14.1.

14.2.15. France

14.2.15.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.2.15.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.2.15.3. Market Revenue and Forecast, by Application (2020-2032)

14.2.15.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.2.16. Market Revenue and Forecast, by Sterility (2020-2032)

14.2.16.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.2.17. Rest of Europe

14.2.17.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.2.17.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.2.17.3. Market Revenue and Forecast, by Application (2020-2032)

14.2.17.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.2.18. Market Revenue and Forecast, by Sterility (2020-2032)

14.2.18.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.3. APAC

14.3.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.3.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.3.3. Market Revenue and Forecast, by Application (2020-2032)

14.3.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.3.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.3.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.3.7. India

14.3.7.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.3.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.3.7.3. Market Revenue and Forecast, by Application (2020-2032)

14.3.7.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.3.8. Market Revenue and Forecast, by Sterility (2020-2032)

14.3.9. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.3.10. China

14.3.10.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.3.10.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.3.10.3. Market Revenue and Forecast, by Application (2020-2032)

14.3.10.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.3.11. Market Revenue and Forecast, by Sterility (2020-2032)

14.3.11.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.3.12. Japan

14.3.12.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.3.12.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.3.12.3. Market Revenue and Forecast, by Application (2020-2032)

14.3.12.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.3.12.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.3.12.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.3.13. Rest of APAC

14.3.13.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.3.13.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.3.13.3. Market Revenue and Forecast, by Application (2020-2032)

14.3.13.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.3.13.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.3.13.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.4. MEA

14.4.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.4.3. Market Revenue and Forecast, by Application (2020-2032)

14.4.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.4.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.4.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.4.7. GCC

14.4.7.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.4.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.4.7.3. Market Revenue and Forecast, by Application (2020-2032)

14.4.7.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.4.8. Market Revenue and Forecast, by Sterility (2020-2032)

14.4.9. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.4.10. North Africa

14.4.10.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.4.10.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.4.10.3. Market Revenue and Forecast, by Application (2020-2032)

14.4.10.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.4.11. Market Revenue and Forecast, by Sterility (2020-2032)

14.4.12. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.4.13. South Africa

14.4.13.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.4.13.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.4.13.3. Market Revenue and Forecast, by Application (2020-2032)

14.4.13.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.4.13.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.4.13.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.4.14. Rest of MEA

14.4.14.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.4.14.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.4.14.3. Market Revenue and Forecast, by Application (2020-2032)

14.4.14.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.4.14.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.4.14.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.5. Latin America

14.5.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.5.3. Market Revenue and Forecast, by Application (2020-2032)

14.5.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.5.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.5.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.5.7. Brazil

14.5.7.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.5.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.5.7.3. Market Revenue and Forecast, by Application (2020-2032)

14.5.7.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.5.8. Market Revenue and Forecast, by Sterility (2020-2032)

14.5.8.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.5.9.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.5.9.3. Market Revenue and Forecast, by Application (2020-2032)

14.5.9.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.5.9.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.5.9.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

Chapter 15. Company Profiles

15.1. Fresenius Kabi

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Fagron NV

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. B. Braun Medical Inc.

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. Rx3 Compounding Pharmacy

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. Clinigen Group PLC

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Dougherty’s Pharmacy, Inc.

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Lorraine’s Pharmacy

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Wedgewood Pharmacy

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. Institutional Pharmacy Solutions

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. Mcguff compounding pharmacy services

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com

---